Guanidine Platinum(II) Complexes: Synthesis, in Vitro Antitumor Activity, and DNA Interactions

Overview

Journal J Inorg Biochem

Specialty Biochemistry

Date 2014 Jan 22

PMID 24444821

Citations 8

Authors

Anton A Legin

Michael A Jakupec

Nadezhda A Bokach

Marina R Tyan

Vadim Yu Kukushkin

Bernhard K Keppler

Affiliations

Soon will be listed here.

Abstract

The novel guanidine compounds trans-[Pt(NH2Me)2{NH=C(NHMe)NR}2](Cl)2 (R=NEt2 [7], NC5H10 [8]) (trans-7,8) were synthesized by the nucleophilic addition of methylamine to dialkylcyanamide ligands of the push-pull nitrile complexes trans-[PtCl2(RCN)2] (R=NEt2, NC5H10). In vitro cytotoxicity tests conducted for the entire series of the guanidine complexes, i.e. trans-7,8, the neutral cis- or trans-[PtCl2{NH=C(NH2)R}2] (cis-1-3 and trans-1-3) and the cationic cis- or trans-[Pt(NH3)2{NH=C(NH2)R}2](Cl)2 (cis-4-6 and trans-4-6) (R=NMe2 [1,4], NEt2 [2,5], NC5H10 [3,6]) in two human cancer cell lines, CH1 (ovarian carcinoma) and SW480 (colon cancer), confirmed that the cytotoxicity of several trans-configured (trans-3,6) complexes is higher than that of cis-congeners (cis-3,6). Cellular platinum levels were analyzed by inductively coupled plasma mass spectrometry upon treatment of SW480 cells, revealing a dependence of cellular accumulation on the geometrical isomerism and the steric hindrance of the variable substituent R on the guanidine ligand. DNA interactions of selected guanidine complexes were studied in order to find hints for the possible reasons for their different activities. Changes induced to the electrophoretic mobility of a dsDNA plasmid confirmed the potency of the guanidine complexes (e.g. trans-1,3,5,6 and cis-1,3,4) to significantly alter DNA secondary structure, indicating DNA as a possible critical target of these compounds.

Citing Articles

Platinum(ii) complexes of aryl guanidine-like derivatives as potential anticancer agents: between coordination and cyclometallation.

OSullivan P, Previtali V, Twamley B, Marmion C, McDonald A, Rozas I RSC Adv. 2025; 15(5):3427-3438.

PMID: 39906633 PMC: 11791622. DOI: 10.1039/d5ra00310e.

Guanidine-Curcumin Complex-Loaded Amine-Functionalised Hollow Mesoporous Silica Nanoparticles for Breast Cancer Therapy.

Viswanathan T, Chitradevi K, Zochedh A, Vijayabhaskar R, Sukumaran S, Kunjiappan S Cancers (Basel). 2022; 14(14).

PMID: 35884549 PMC: 9323383. DOI: 10.3390/cancers14143490.

DNA Conformational Changes Induced by Its Interaction with Binuclear Platinum Complexes in Solution Indicate the Molecular Mechanism of Platinum Binding.

Kasyanenko N, Qiushi Z, Bakulev V, Sokolov P, Yakovlev K Polymers (Basel). 2022; 14(10).

PMID: 35631926 PMC: 9143540. DOI: 10.3390/polym14102044.

Quercetin as a Precursor for the Synthesis of Novel Nanoscale Cu (II) Complex as a Catalyst for Alcohol Oxidation with High Antibacterial Activity.

Moodi Z, Bagherzade G, Peters J Bioinorg Chem Appl. 2021; 2021:8818452.

PMID: 33747070 PMC: 7952193. DOI: 10.1155/2021/8818452.

Evaluation of Metal Oxide Surface Catalysts for the Electrochemical Activation of Amino Acids.

Tooley C, Gasperoni C, Marnoto S, Halpern J Sensors (Basel). 2018; 18(9).

PMID: 30231497 PMC: 6164431. DOI: 10.3390/s18093144.

References

Egger A, Rappel C, Jakupec M, Hartinger C, Heffeter P, Keppler B . Development of an experimental protocol for uptake studies of metal compounds in adherent tumor cells. J Anal At Spectrom. 2012; 24(1):51-61. PMC: 3378211. DOI: 10.1039/B810481F. View

Kalinowska U, Matlawska K, Checinska L, Domagala M, Kontek R, Osiecka R . Synthesis, spectroscopy and antiproliferative activity of cis- and trans-platinum(II) complexes with diethyl (pyridin-4-ylmethyl)phosphate. X-ray crystal structure of trans-Pt(II) complex. J Inorg Biochem. 2005; 99(10):2024-31. DOI: 10.1016/j.jinorgbio.2005.06.030. View

Najajreh Y, Ardeli-Tzaraf Y, Kasparkova J, Heringova P, Prilutski D, Balter L . Interactions of platinum complexes containing cationic, bicyclic, nonplanar piperidinopiperidine ligands with biological nucleophiles. J Med Chem. 2006; 49(15):4674-83. DOI: 10.1021/jm060238j. View

Jung Y, Lippard S . Direct cellular responses to platinum-induced DNA damage. Chem Rev. 2007; 107(5):1387-407. DOI: 10.1021/cr068207j. View

Bartel C, Bytzek A, Scaffidi-Domianello Y, Grabmann G, Jakupec M, Hartinger C . Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds. J Biol Inorg Chem. 2012; 17(3):465-74. DOI: 10.1007/s00775-011-0869-5. View

Ma E, Bates W, Edmunds A, Kelland L, Fojo T, Farrell N . Enhancement of aqueous solubility and stability employing a trans acetate axis in trans planar amine platinum compounds while maintaining the biological profile. J Med Chem. 2005; 48(18):5651-4. DOI: 10.1021/jm050539d. View

Marzano C, Sbovata S, Gandin V, Colavito D, Del Giudice E, Michelin R . A new class of antitumor trans-amine-amidine-Pt(II) cationic complexes: influence of chemical structure and solvent on in vitro and in vivo tumor cell proliferation. J Med Chem. 2010; 53(16):6210-27. DOI: 10.1021/jm1006534. View

Kelland L . The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 2007; 7(8):573-84. DOI: 10.1038/nrc2167. View

Bokach N, Pakhomova T, Kukushkin V, Haukka M, Pombeiro A . Hydrolytic metal-mediated coupling of dialkylcyanamides at a Pt(IV) center giving a new family of diimino ligands. Inorg Chem. 2003; 42(23):7560-8. DOI: 10.1021/ic034800x. View

10.

Boccarelli A, Intini F, Sasanelli R, Sivo M, Coluccia M, Natile G . Synthesis and in vitro antitumor activity of platinum acetonimine complexes. J Med Chem. 2006; 49(2):829-37. DOI: 10.1021/jm050986t. View

11.

Scaffidi-Domianello Y, Legin A, Jakupec M, Arion V, Kukushkin V, Galanski M . Synthesis, characterization, and cytotoxic activity of novel potentially pH-sensitive nonclassical platinum(II) complexes featuring 1,3-dihydroxyacetone oxime ligands. Inorg Chem. 2011; 50(21):10673-81. DOI: 10.1021/ic2010612. View

12.

Pourahmad J, Hosseini M, Eskandari M, Shekarabi S, Daraei B . Mitochondrial/lysosomal toxic cross-talk plays a key role in cisplatin nephrotoxicity. Xenobiotica. 2010; 40(11):763-71. DOI: 10.3109/00498254.2010.512093. View

13.

Casini A, Gabbiani C, Mastrobuoni G, Pellicani R, Intini F, Arnesano F . Insights into the molecular mechanisms of protein platination from a case study: the reaction of anticancer platinum(II) iminoethers with horse heart cytochrome c. Biochemistry. 2007; 46(43):12220-30. DOI: 10.1021/bi701516q. View

14.

Marzano C, Sbovata S, Bettio F, Michelin R, Seraglia R, Kiss T . Solution behaviour and biological activity of bisamidine complexes of platinum(II). J Biol Inorg Chem. 2007; 12(4):477-93. DOI: 10.1007/s00775-006-0202-x. View

15.

Wu F, Lin X, Okuda T, Howell S . DNA polymerase zeta regulates cisplatin cytotoxicity, mutagenicity, and the rate of development of cisplatin resistance. Cancer Res. 2004; 64(21):8029-35. DOI: 10.1158/0008-5472.CAN-03-3942. View

16.

Quasthoff S, Hartung H . Chemotherapy-induced peripheral neuropathy. J Neurol. 2002; 249(1):9-17. DOI: 10.1007/pl00007853. View

17.

Coluccia M, Nassi A, Boccarelli A, Giordano D, Cardellicchio N, Locker D . In vitro and in vivo antitumour activity and cellular pharmacological properties of new platinum-iminoether complexes with different configuration at the iminoether ligands. J Inorg Biochem. 2000; 77(1-2):31-5. DOI: 10.1016/s0162-0134(99)00139-7. View

18.

Tyan M, Bokach N, Wang M, Haukka M, Kuznetsov M, Kukushkin V . Facile cyanamide-ammonia coupling mediated by cis- and trans-[PtIIL2] centers and giving metal-bound guanidines. Dalton Trans. 2008; (38):5178-88. DOI: 10.1039/b806862c. View

19.

Quiroga A, Cubo L, de Blas E, Aller P, Navarro-Ranninger C . Trans platinum complexes design: one novel water soluble oxime derivative that contains aliphatic amines in trans configuration. J Inorg Biochem. 2006; 101(1):104-10. DOI: 10.1016/j.jinorgbio.2006.08.012. View

20.

Zorbas-Seifried S, Jakupec M, Kukushkin N, Groessl M, Hartinger C, Semenova O . Reversion of structure-activity relationships of antitumor platinum complexes by acetoxime but not hydroxylamine ligands. Mol Pharmacol. 2006; 71(1):357-65. DOI: 10.1124/mol.106.030726. View